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Abstract
Background: Polyethylene glycosylated (PEGylated) porcine glucagon-like peptide-2 (pGLP-2) considerably
increases half-life and stability compared with the native pGLP-2, but the effective dose for intestinal damage is still
unclear. This study aims to evaluate the available dose of polyethylene glycosylated porcine glucagon-like peptide-2
(PEG-pGLP-2), a modified, long-acting form of pGLP-2 in an experimental rat model of ulcerative colitis.
Methods: Thirty-five male rats were randomly assigned into five groups: control, dextran sodium sulphate (DSS),
DSS + PEG–pGLP-2(L), DSS + PEG–pGLP-2(M) and DSS + PEG–pGLP-2(H). Rats in control group received only water;
other rats were fed with 5% (w/v) DSS and intraperitoneally administered with 12.5, 25 and 100 nmol/kg
PEG–pGLP-2 daily for 6 days.
Results: Compared with the control treatment, DSS treatment significantly (p < 0.05) decreased body weight
change, colonic length, duodenal villus height and expression of zonula occludens-1, whereas significantly (p < 0.05)
increased colonic damage score and expression of claudin-1, interleukin (IL)-1, IL-7, IL-10, interferon-γ and tumour
necrosis factor (TNF)-α in colon. However, the three doses of PEG–pGLP-2 all reduced these effects; these
treatments significantly (p < 0.05) increased body weight change and duodenal villus height, whereas significantly
(p < 0.05) decreased colonic damage score and expression of IL-1, IL-7 and TNF-α in colon. Specifically, low-dose
(12.5 nmol/kg/d) PEG–pGLP-2 was effective.
Conclusions: These results indicated that PEG–pGLP-2 is a novel and potentially effective therapy for intestinal
healing in a relatively low dose.
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Background
Frequent injection of porcine glucagon-like peptide-2
(pGLP-2) because of the rapid degradation of pGLP-2 by
the enzyme dipeptidyl peptidase-IV (DPP-IV) is the
main impediment of pGLP-2 as a potential therapeutic
agent for intestinal dysfunction and damage in weaning
piglets [1]. For the first time, our team designed and
purified polyethylene glycosylated (PEGylated) pGLP-2
(PEG-pGLP-2), whose half-life (t1/2) is 16-fold longer
than that of pGLP-2 in DPP-IV in vitro [2]. PEG-pGLP-
2 infusion could alleviate the severity of intestinal injury
in weaning piglets [3, 4]. The t1/2 of teduglutide, a GLP-
2 analogue, which is a candidate for the treatment of
short bowel syndrome (SBS) in two phase III clinical
studies [5], is 2.99 h in male patient [6]. Recently, our
team proved that the t1/2 of PEG-pGLP-2 is 3.38 h in
male rats [7]. These findings provide a new perspective
to the potential therapeutic use of PEG-pGLP-2 for
weaning and diarrhoeal diseases in young pigs.
However, no reports about the therapeutic effect of
PEG-pGLP-2, except that of our team, are available.
Little information is also known about the dose and fre-
quency of administration with PEG-pGLP-2. Thymann
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et al. [8] found that injection of acylated GLP-2 analogue
25 μg/(kg BW · 12 h) for 5 days increases intestinal
weight and activity of brush border enzymes in weaned
pigs when only using long-acting analogues or under
diarrhoeal conditions. Kaji et al. [9] demonstrated high
doses (240 μg/kg/day for 5 days) of continuous infusion
result in the largest increases in microscopic and gross
intestinal morphologic parameters in parenterally main-
tained rats. Similarly, Nakame et al. [10] found that high
dose of GLP-2 (800 μg/kg BW every 6 h before stress)
administration improves the incidence and survival rate
of necrotising enterocolitis (NEC) in rats. Nevertheless,
Sigalet et al. [11] found the effects of subcutaneous in-
jection of weaning pigs with GLP-2 at a dose of 40 μg/
kg/day for 42 days are limited to the gastrointestinal
tract; GLP-2 could increase crypt cell proliferation rates
and decrease in apoptosis; no effects were observed on
activity, appetite, behaviour or food intake. Deng et al.
[12] found that both low and high doses of exogenous
GLP-2 (2 or 10 nmol/kg BW per day for 7 consecutive
days) improve the growth of weaned piglets and protect
them against LPS-induced intestinal damage. The vari-
ous results of therapeutic methods of GLP-2 may be
caused by the different agents, experimental animals and
test environments. However, the substantially long t1/2
of PEG-pGLP-2 provides us confidence to utilise it for
post-weaning diarrhoea syndrome.
The present study was designed to examine the effect of
different doses of long-acting pGLP-2, that is, PEG-
p[Gly2]GLP-2, on growth performance, intestinal morph-
ology and expression levels of tight junction (TJ) proteins
and inflammatory cytokines in an experimental rat model
of ulcerative colitis. Results of this study may provide the




Porcine [Gly2] GLP-2 (HGDGSFSDEMNTVLDNLATRD-
FINWLLHTKITDSL, > 98%) was synthesised by Chinese
Peptide Company (Hangzhou, China). Monomethoxy
PEG–succinimidyl propionate (mPEG–SPA; molecular
weight (MW) = 5 kDa) was purchased from Beijing
Kaizheng Biotech Development Co., Ltd. (Beijing,
China). The ion-exchange chromatography (IEC) resin
and column used were CM Sepharose Fast Flow (GE
Healthcare Bio-Science AB, Uppsala, Sweden). Ultrafiltra-
tion membranes with a MW cutoff of 3000 were purchased
from Millipore Corporation (Billerica, MA, USA). Dextran
sodium sulphate (DSS) (MW=36 000–50 000) was pur-
chased from MP Biomedicals China (Shanghai, China).
RNAiso Plus, PrimeScript®RT-reagent with gDNA Eraser
Kit and SYBR® Premix Ex TaqTM were purchased from
Takara Biotechnology Co., Ltd. (Dalian, China). RNA locker
was purchased from TIANDZ (Beijing, China). Unless
otherwise specified, all other chemicals and reagents
were of analytical grade from Sigma–Aldrich and Fluka
(Milan, Italy).
Preparation of PEG-p[Gly2]GLP-2
The mono-PEGylated p[Gly2]GLP-2 conjugates were
prepared and purified as previously described [3]. Briefly,
1 mg/mL of p[Gly2]GLP-2 in 50 mmol/L Tris-HCl buffer
solution was reacted with 4 mole excess of mPEG5k-SPA
at room temperature for 30 min. The reaction was
quenched by 1% trifluoroacetic acid/deionised water.
The PEGylated p[Gly2]GLP-2 mixtures were separated
with IEC with C M Sepharose Fast Flow resin. The
equilibration phase was 20 mmol/L of acetate buffer
(pH 4.0), and the elution phase was 20 mmol/L acetate
buffer (pH 4.0) + 1 mol/L NaCl. The PEGylated
p[Gly2]GLP-2 products were eluted in a linear gradient
ranging from 0 to 60% for 60 min and to 100% for
30 min with 1 mL/min of elution buffer at 215 nm. The
PEGylated products were collected, desalted, concen-
trated through 3 kDa cutoff, ultrafitrated and lyophilised
to powder before the animal study.
Animal ethics statement and experimental protocol
Animal studies were conducted in accordance with the
guidelines of the Zhejiang Farm Animal Welfare Council
of China and approved by the ethics committee of
Zhejiang Academy of Agricultural Sciences. Thirty-
five male Sprague–Dawley rats were allocated into
five treatments: control, DSS, DSS + PEG–pGLP-2(L),
DSS + PEG–pGLP-2(M) and DSS + PEG–pGLP-2(H).
Each treatment was performed in seven replicates on
one rat. The rats were housed in a plastic bottom, wire-lid
cages, maintained on a 12 h: 12 h light–dark cycle and
allowed to acclimatise to the animal facility for 3 days. Rats
in control group received only water; other rats were fed
with 5% (w/v) DSS through their drinking water for 6 days
from the first day of experiment, followed by 2 days of
water consumption. The rats from the DSS + PEG–pGLP-
2(L), DSS + PEG–pGLP-2(M) and DSS + PEG–pGLP-2(H)
groups were intraperitoneally administered with 12.5, 25
and 100 nmol/kg PEG–pGLP-2, respectively, in 0.3 mL of
saline solution daily from day 1 to day 6 of the trial. The
rats in the control and DSS groups were administered with
the same volume of saline solution. During the experimen-
tal period, behaviour and body weight were monitored
daily. On day 8, all rats were anesthetised and sacrificed to
collect their intestinal sample.
Collection samples
Samples collection was prepared as previously described
[4]. The segment from the pylorus to the Trietz ligament
and from the ileocecal valve to the rectum was
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considered the duodenum and colon, respectively; these
segments were cut free from their mesentery and imme-
diately placed on ice. The duodenum and colon were
cleaned of luminal contents, weighed and measured with
a balance and a ruler. The middle segments (1 cm) of
duodenum and colon were fixed in 10% formalin for
48 h and embedded in paraffin using standard tech-
niques for histology. One centimetre of the distal seg-
ment of colon was collected for RNA isolation, which
was immediately placed in 1 mL of RNA locker.
Histology
Histology was prepared as previously described [3]. The
paraffin-embedded sections were cut at 4 μm thickness
and stained with haematoxylin and eosin. Duodenum
villus-plus-crypt height was imaged using an Olympus
DP-71 digital camera, and quantification was performed
using an image processing system. Approximately 12
longitudinally oriented villi were measured from each
H&E-stained section to make n = 1. All measurements
were performed in a blinded manner. Colonic damage
score (CDS), was evaluated in a blinded manner in tissue
sections based on a grade scale ranging from 0 to 3 to
measure the amount and depth of inflammation. The
amount of crypt damage or regeneration was measured
in a scale of 0–4, as indicated in Dieleman et al. [13].
These changes were also quantified in terms of the per-
centage involvement of the disease process: (1) 1–25%,
(2) 26–50%, (3) 51–75% and (4) 76–100%. Each section
was separately scored for each feature by establishing
the product of the grade for that feature and the
percentage involvement. The sum of the products of the
four scores was the CDS for each rat.
Real-time PCR
Total RNA was isolated using RNAiso Plus kits follow-
ing the manufacturers’ instructions [4]. A 2 μL aliquot
of the total RNA was used for first-strand cDNA synthe-
sis using PrimeScript® RT-reagent Kit with gDNA Eraser.
Real-time PCR was carried out with ABI plus one (Life
Technologies, Carlsbad, CA, USA) using SYBR Premix
Ex TaqTM. The primers used were in Table 1. RT-PCR
analysis was performed with an ABI Step One Plus Real-
Time PCR System (Applied Biosystems, Inc.) using
SYBR® Premix Ex TaqTM. PCR reactions were per-
formed in triplicate under the following conditions: 95 °C
for 30 s; 40 cycles of 95 °C for 5 s and 60 °C for 30 s.
Fluorescent data for quantification were collected at the
end of each cycle. Melting curve analysis was performed
at 55–95 °C to verify the single product generation at the
end of the assay. Standard curves were generated based
on the data obtained from the standards of the 2–2−6
dilution series template. Standard curve analysis was
performed by using Step One Software (v2.2, Applied
Biosystems, Inc.). Data were normalised to GADPH
using the 2−△△Ct quantitation method.
Statistical analysis
Data are expressed as the mean ± SD. Statistical differ-
ences between groups were compared through ANOVA




As shown in Table 2, compared with the control treat-
ment, the rats treated with 5% DSS for 6 days exhibited
significantly decreased body weight change and colonic
length (p < 0.05). Compared with the DSS group, body
weight change and ratio between colonic weight and
body weight of rats in DSS + PEG–pGLP-2(L) and DSS +
PEG–pGLP-2(M) groups significantly (p < 0.05) increased,
and the colonic length of rats in DSS + PEG–pGLP-2(L)
group significantly (p < 0.05) increased; the body weight
change in DSS + PEG–pGLP-2(H) also significantly
(p < 0.05) increased. No significant differences in in-
testinal length and ratio of intestinal weight/body
weight were observed among the five groups.
Table 1 Primer sequences (5′ to 3′) used for the quantitative polymerase chain reaction
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CDS of colon
The colonic morphology and CDS of the rats from the
five treatments are shown in Fig. 1a–f. Compared with
the control treatment, the CDS (Fig. 1f ) of colon in rats
of DSS group significantly (p < 0.05) increased, which
was characterised as induced oedema of the intestinal
wall, mucous epithelium destruction and multifocal
dropouts of entire crypts in a large part of the colon
(Fig. 1b). Compared with DSS group, the CDS (Fig. 1f) of
colon in rats of DSS + PEG–pGLP-2(L) (Fig. 1c), DSS +
Table 2 Effects of polyethylene glycosylated (PEGylated) porcine glucagon-like peptide-2 (pGLP-2) on growth performance of colitis rats




Control 30.48 ± 3.44a 94.72 ± 4.93 15.69 ± 1.90a 30.61 ± 2.22 11.19 ± 1.90b
Dextran sodium sulphate (DSS) 11.90 ± 5.04c 92.88 ± 9.78 12.40 ± 1.94b 35.19 ± 1.22 9.15 ± 1.79b
DSS + PEG–pGLP-2(L) 21.45 ± 2.00b 94.50 ± 7.07 14.74 ± 1.90a 34.51 ± 3.09 14.13 ± 2.77a
DSS + PEG–pGLP-2(M) 21.46 ± 4.65b 99.10 ± 8.03 14.48 ± 1.42ab 38.91 ± 4.23 14.22 ± 0.38a
DSS + PEG–pGLP-2(H) 20.63 ± 3.4b 99.56 ± 6.82 13.42 ± 0.80ab 35.87 ± 1.73 11.52 ± 0.64b
Data are expressed as means ± SD; no significant difference exists in that with no letter or the same letters (p > 0.05), and different letters (p < 0.05) indicate
statistically significant difference
Fig. 1 Effects of PEG-pGLP-2 on the morphology and inflammation score of colon. a, b, c, d, e is the morphology of colon in group of Control,
DSS, DSS + PEG–pGLP-2(L), DSS + PEG–pGLP-2(M), DSS + PEG–pGLP-2(H). Data of the colonic inflammation score (f) are expressed as means ± SD
and different letters (p < 0.05) indicate statistically significant difference
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PEG–pGLP-2(M) (Fig. 1d) and DSS + PEG–pGLP-2(H)
(Fig. 1e) groups significantly (p < 0.05) decreased; such
change was characterised as slight oedema of the intestinal
wall, reconstruction of the mucous epithelium, increased
goblet cells and decreased multifocal dropouts and
focal lesions inflammatory cells; particularly, the colon
morphological structures of DSS + PEG–pGLP-2(M)
(Fig. 1d) and DSS + PEG–pGLP-2(H) (Fig. 1e) group
were almost normal with no damage.
Morphology of duodenum
As shown in Table 3, compared with the control
treatment, the villi height of duodenum in rats of
DSS group significantly (p < 0.05) decreased. Com-
pared with DSS group, the villi height of duodenum
in rats of DSS + PEG–pGLP-2(L), DSS + PEG–pGLP-
2(M) and DSS + PEG–pGLP-2(H) groups significantly
(p < 0.05) increased, and the ratio of villi height/crypt
depth in rats of DSS + PEG–pGLP-2(M) group signifi-
cantly (p < 0.05) increased. No significant differences
in crypt depth of duodenum in rats were observed
among the five groups.
Expression of TJ and inflammation cytokines in colon
The expression levels of TJ proteins in colon are shown
in Fig. 2a–c. Compared with the control treatment, the
expression of zonula occludens-1(ZO-1) (Fig. 2a) in rats
of DSS group significantly (p < 0.05) decreased, whereas
the expression of claudin-1 (Fig. 2c) in rats of DSS group
significantly (p < 0.05) increased. Compared with DSS
group, the expression of ZO-1 (Fig. 2a) in rats of
DSS + PEG–pGLP-2(H) and occludin (Fig. 2b) in rats
of DSS + PEG–pGLP-2(M) and DSS + PEG–pGLP-2(H)
groups significantly (p < 0.05) increased; moreover, the
expression of claudin-1 (Fig. 2c) in rats of DSS +
PEG–pGLP-2(M) and DSS + PEG–pGLP-2(H) group
significantly (p < 0.05) decreased.
The expression levels of inflammatory cytokines in
colon are shown in Fig. 2d–i. Compared with the control
treatment, the expression of interleukin (IL)-1 (Fig. 2d),
IL-7 (Fig. 2f), IL-10 (Fig. 2g), interferon-γ (IFN-γ) (Fig. 2h)
and tumour necrosis factor-α (TNF-α) (Fig. 2i) in rats of
DSS group significantly (p < 0.05) increased. Compared
with DSS group, the expression of IL-1 (Fig. 2d), IL-7
(Fig. 2f) and TNF-α (Fig. 2i) in rats of DSS + PEG–pGLP-
2(L), DSS + PEG–pGLP-2(M) and DSS + PEG–pGLP-2(H)
groups significantly (p < 0.05) decreased; the expression
of IL-10 (Fig. 2g) in rats of DSS + PEG–pGLP-2(L) and
DSS + PEG–pGLP-2(M) groups significantly (p < 0.05)
decreased; the expression of IFN-γ (Fig. 2h) in rats of
DSS + PEG–pGLP-2(M) group significantly (p < 0.05)
decreased. No significant differences in the expression
of IL-6 (Fig. 2e) in colon of rats were observed among
the five groups.
Discussion
This study is the first about the therapeutic effects of
different doses of PEGylated pGLP-2 on DSS-induced
colitis in rats. In this experiment, administration of 12.5,
25 or 100 nmol/kg/d PEG–pGLP-2 for 6 days could re-
duce the severity of colitis, improve the body weight and
colonic weight, and decrease the production of inflam-
matory cytokines. PEG–p[Gly2]GLP-2 at 12.5 nmol/kg/d
for 6 days is effective for recovering the colonic damage
by DSS, which is indicated by colonic weight, length,
damage score and expression of inflammatory cytokines
(IL-1, IL-7, IL-10 and TNF-α).
DSS-induced ulcerative colitis is a reproducible model
with symptoms of weight loss and colon shortening.
GLP-2 can prevent DSS damage in mice, reverse body
weight loss, decrease colonic inflammation and increase
colonic integrity [14, 15], and the PEG-pGLP-2 here
showed similar effects. There were some intreasting
results in this study. First, PEG-pGLP-2 reduced the
expression of both inflammation cytokines (IL-1, IL-7,
TNF-α) and anti-inflammation cytokines (IL-10). Which
was similar to previous reports regarding dextran
sulphate-induced colitis [14, 16] and weaning piglets
challenged with LPS [4]. Ivory et al. [17] demonstrated the
anti-inflammation effects of GLP-2 are IL-10 independent
in IL-10 knockout mouse. The anti-inflammatory effects
of GLP-2 were assumed to be associated with the in-
creased crypt proliferation and decreased crypt apoptosis,
which presumably aid healing of lesions and subsequently
reduce the production of inflammatory cytokines [18].
Second, expression of tight junction protein ZO-1 and
Table 3 Effects of PEG-pGLP-2 on morphology of duodenum in colitis rats
Groups Villus height, μm Crypt depth, μm Villus height/Crypt depth
Control 1016.37 ± 49.60a 401.79 ± 57.00 2.22 ± 0.12b
DSS 777.99 ± 104.34b 337.15 ± 30.19 2.28 ± 0.16b
DSS + PEG–pGLP-2(L) 981.46 ± 136.04a 400.76 ± 62.04 2.66 ± 0.49ab
DSS + PEG–pGLP-2(M) 1006.42 ± 98.11a 357.43 ± 52.21 2.98 ± 0.49a
DSS + PEG–pGLP-2(H) 1003.03 ± 96.41a 419.63 ± 51.00 2.39 ± 0.30b
Data are expressed as means ± SD; no significant difference exists in that with no letter or the same letters (p > 0.05), and different letters (p < 0.05) indicate
statistically significant difference
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Occludin increased while the tight junction protein
Claudin-1 decreased. Tight junctions is an important
junctional complex in epithelial cells, and contains
several unique proteins, namely, claudins, the trans-
membrane protein occludin and ZOs [19]. The impact of
GLP-2 on the TJ proteins (ZO-1 and occludin) of the
jejunum epithelia was confirmed by immunofluorescence
staining in ob/ob mice injected with GLP-2 [20]. The
different changes of Claudin-1 in tight junction protein
could be explained by a possible compensatory role for
claudin-1 in the damaged TJ of Poritz et al. [21], which
found in dextran sulfate sodium (DSS) model of colonic in-
flammation, a decrease in ZO-1 but also a counterintuitive
increase in claudin-1.
Effects of exogenous GLP-2 or its long-acting ana-
logues on intestinal growth and healing have been
studied in different animal models. Early time, the effect-
ive dose of GLP-2 is considerably high; Kato et al. [22]
demonstrated that GLP-2 can enhance normal rat small
intestine mucosal mass and absorption at 50 mg/kg/d
for 14 days. The findings of Thymann et al. [8] may
explain the above result; they found that animal living
environment (normal animal or with disease) and modi-
fied GLP-2 are important for the intestinal therapeutic
effects for piglets. Thymann et al. [8] also found that the
significant effects of GLP-2 improve gut structure and
function in weanling pigs only under diarrhoeal condi-
tions and when using long-acting GLP-2 analogues.
Thus, the dose of native GLP-2 shows relatively high ef-
fect. Nakame et al. [10] found subcutaneous administra-
tion of 800 μg/kg/day (224 nmol/kg/d) GLP-2 for 4 days
could reduce the severity of NEC and improve the
survival rate in rats. In the study of Kaji et al. [9],
the continuous infusion of 240 μg/kg/day (67 nmol/
kg/d) GLP-2 for 5 days induces intestinal growth and
increases weight gain using a total parenteral nutri-
tion (TPN) supported model in the rat. Thymann et
al. [8] found that 200 μg/ kg · 12 h (56 nmol/kg ·
12 h) GLP-2 for 7 days only increases goblet cell
density, but shows limited effects on diarrhoea. No
differences exist between two regimens (continuous
GLP-2 infusion versus three daily GLP-2 injections)
of 1 mg/day GLP-2 for 21 days on intestinal absorption in
SBS patients [23]. Infusion of 100 μg/kg/d GLP-2 for
7 days augments adaptive growth and digestive capacity of
the residual small intestine in a rat model of mid–small
bowel resection [24]. Injection duration is also a major
factor influencing the therapeutic effects. Sigalet et al.
showed that chronic treatment of weaning pigs with GLP-
2 at 40 μg/kg/day given by s.c. injection twice daily for
42 days increases the overall villus height and crypt depth;
no effects were observed on activity, appetite, behaviour
or food intake in weaning pigs [11].
However, when the peptide chain is changed or modi-
fied, the effective dose of GLP-2 is considerably low.
L’Heureux and Brubaker (2003) used 40 μg/kg · q12 h
Fig. 2 Effects of PEG-pGLP-2 on the expression levels of tight junction proteins and inflammatory cytokines in colon of colitis rats. a, b, c
is the expression levels of ZO-1, Occludin and Claudin-1. d, e, f, g, h, i is the expression levels of IL-1, IL-6, IL-7, IL-10, IFN-γ andTNF-α.
Data are expressed as means ± SD; no significant difference exists in that with no letter or the same letters (p > 0.05), and different letters
(p < 0.05) indicate statistically significant difference
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(11.5 nmol/kg · 12 h) human [Gly2] GLP-2 for 10 con-
secutive days, which increases survival and small intes-
tinal weight, and decreases body weight loss and colonic
damage in DSS-mice [18]. Thymann et al. [8] found
that 25 μg/ kg · 12 h of a long-acting acylated GLP-2
analogue for 5 days increases intestinal weight and
activity of brush border enzymes in a low-sanitary
environment. Pretreatment with a long-acting DPPIV
inhibitor K579 (1 mg/kg, ig) for 1 day prevents the forma-
tion and promotes healing of IND-induced intestinal
ulcers, although high-dose K579 (3 mg/kg) reverses the
preventive effect [25]. Teduglutide, a DPP-IV-resistant
GLP-2 analogue given subcutaneously for 21 days at three
dose levels (30, 100 and 150 μg/kg/day), significantly in-
creases intestinal wet weight absorption in SBS patients
[26]. In the study of a neonatal piglet jejunostomy model
by Thymann et al. [27], a dose-dependent (0.01, 0.02, 0.1
or 0.2 mg/kg/day teduglutide) increase in weight per
length of the remnant intestine is obtained, but functional
and structural endpoints, including digestive enzyme ac-
tivity and enteral nutrient absorption, are not affected by
treatments. XTEN is a long, unstructured, non-repetitive,
hydrophilic sequence of amino acids. With the fusion of
XTEN to the C-terminus of GLP2-2G, the serum half-life
of GLP2-2G-XTEN in rats is 38 h, and 25 nmol/kg/day
GLP2-2G-XTEN for 12 days significantly increases the
length, reduces the number of trans-ulcerations and
adhesions, and reduces the TNF-α content of the small
intestine in rat indomethacin-induced disease model [28].
PEGylated pGLP-2, a site-specific mono-PEGylated
derivative, was designed and purified by our team. This
derivative exhibits longer half-life than native pGLP-2 in
vitro and can reduce the severity of colonic injury in
murine colitis [2]. We demonstrated that 10 nmol/kg/d
PEG–pGLP-2 infusion alleviates the severity of intestinal
injury in weaning piglets challenged with LPS by reducing
the secretion of inflammatory cytokines and increasing
the villus height/crypt depth ratio [3]. To provide refer-
ences for the intestinal injury of weaned pigs by PEG–
p[Gly2]GLP-2, the pharmacokinetics of PEG–p[Gly2]GLP-
2 was conducted. The results showed that the half-life of
p[Gly2]GLP-2 and PEG–p[Gly2]GLP-2 is 49 and 202 min
in rat, respectively, which is longer than the half-life of
intact pGLP-2 (8.4 min) [1]. PEGylated p[Gly2]GLP-2 sig-
nificantly improves the pharmacological profiles; increases
half-time, peak time and mean residence time; decreases
reduce clearance rate; and improves bioavailability [7]. Lee
et al. [29] used a similar methodology to project the half-
life of the GLP-1fusion; PEG(2 k)-Lys-GLP-1 improves the
half-life with a 16- and 3.2-fold increase for intravenous
and subcutaneous administrations, respectively.
The present study mainly aims to provide the dose
reference for application of PEG-pGLP-2 in weaned pig.
The effective dose of GLP-2 in pig is relatively low. Both
low (2 nmol/kg BW/day) or high (10 nmol/kg BW/day)
dose of human [Gly2]GLP-21–34 2 for 7 days improves
the growth of weaned piglets and protects them against
LPS-induced intestinal damage [12]. TPN-fed neonatal
piglets with infused iv at three rates (2.5, 5.0 and
10.0 nmol/kg/d) of GLP-2 for 7 days exhibit increased
small intestinal weight, DNA and protein content,
and villus height [30]. This observation may be ex-
plained by the long half-life in different animals. Al-
ters et al. [28] demonstrated that the serum half-life
of GLP2-2G-XTEN in mice, rats and monkeys is 34,
38 and 120 h, respectively. Therefore, the longer half-
life of PEG–p[Gly2]GLP-2 implies a lower total dose
requirement in weaned piglet.
Conclusions
Our results demonstrated three doses (12.5, 25 or
100 nmol/kg/d) of PEG–pGLP-2, a long-acting pGLP-2,
reduces the ulcerative colitis in male rats by recovering
the body weight, colonic length, colonic damage score and
production of inflammatory cytokines. PEG–pGLP-2 is a
novel and potentially effective therapy for intestinal heal-
ing in a relatively low molar dose (12.5 nmol/kg/d).
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